Challenges on Multiple Endpoints in Clinical Trials: An Industry Survey in Japan

被引：0

作者：

Kentaro Sakamaki

Seitaro Yoshida

Yusuke Morita

Toshifumi Kamiura

Katsuhiro Iba

Naoyuki Ogawa

Hideki Suganami

Satoru Tsuchiya

Satoru Fukimbara

机构：

[1] The University of Tokyo,Department of Biostatistics and Bioinformatics

[2] Yokohama City University,Center for Data Science

[3] Japan Pharmaceutical Manufacturers Association,Data Science Expert Committee, Drug Evaluation Committee

[4] Chugai Pharmaceutical Co,Clinical Information & Intelligence Department

[5] Ltd,Clinical Data Science and Affairs

[6] Kyorin Pharmaceutical Co,Data Science Department

[7] Ltd,Department of Biometrics

[8] Nippon Shinyaku Co,Clinical Development Department

[9] Ltd,Clinical Data Science Department

[10] Otsuka Pharmaceutical Co,Data Science

[11] Ltd,Data Science

[12] Sanwa Kagaku Kenkyusho Co,undefined

[13] Ltd,undefined

[14] Kowa Company,undefined

[15] Ltd,undefined

[16] Sumitomo Dainippon Pharma Co,undefined

[17] Ltd,undefined

[18] Ono Pharmaceutical Co,undefined

[19] Ltd,undefined

来源：

Therapeutic Innovation & Regulatory Science | 2020年 / 54卷

关键词：

multiple endpoints; terminology; determination of endpoint; multiplicity adjustment; industry survey;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：528 / 533

页数：5

共 50 条

[21] One-sided tests in clinical trials with multiple endpoints
Bloch, DA
Lai, TL
Tubert-Bitter, P
BIOMETRICS, 2001, 57 (04) : 1039 - 1047
[22] Opportunities and challenges of clinical trials in cardiology using composite primary endpoints
Rauch, Geraldine
Rauch, Bernhard
Schueler, Svenja
Kieser, Meinhard
WORLD JOURNAL OF CARDIOLOGY, 2015, 7 (01): : 1 - 5
[23] Exploring Novel Endpoints for Clinical Trials in Kidney Disease: Challenges and Opportunities
Roy-Chaudhury, Prabir
KIDNEY INTERNATIONAL REPORTS, 2017, 2 (03): : 295 - 296
[24] Challenges to multiple testing in clinical trials
Hung, H. M. James
Wang, Sue-Jane
BIOMETRICAL JOURNAL, 2010, 52 (06) : 747 - 756
[25] Endpoints in lung cancer trials: Today's challenges for clinical statistics
Pilz L.R.
Manegold C.
memo - Magazine of European Medical Oncology, 2013, 6 (2) : 92 - 97
[26] Multiplicity adjustment for multiple endpoints in clinical trials with multiple doses of an active treatment
Quan, H
Luo, XH
Capizzi, T
STATISTICS IN MEDICINE, 2005, 24 (14) : 2151 - 2170
[27] Clinical trials: Surrogate endpoints or hard endpoints?
Kuller, LH
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (2A): : 59E - 61E
[28] Clinical Meaning and Operability of Endpoints in Cancer Clinical Trials: Example of Survey on RMST Threshold
Ohashi, Yasuo
ANNALS OF ONCOLOGY, 2019, 30
[29] Endpoints in oncology clinical trials
Kilickap, Saadettin
Demirci, Umut
Karadurmus, Nuri
Dogan, Mutlu
Akinci, Bulent
Sendur, Mehmet Ali Nahit
JOURNAL OF BUON, 2018, 23 : S1 - S6
[30] Composite endpoints in clinical trials
Ferreira-Gonzalez, Ignacio
Alonso-Coello, Pablo
Sola, Ivan
Pacheco-Huergo, Valeria
Domingo-Salvany, Antonia
Alonso, Jordi
Montori, Victor
Permanyer-Miralda, Gaieta
REVISTA ESPANOLA DE CARDIOLOGIA, 2008, 61 (03): : 283 - 290

← 1 2 3 4 5 →